

# **IgA Immunotherapy**

## **the therapeutic alternative to treat mucosal cancers**

Armelle Cuvillier

President/C.S.O

[armelle.cuvillier@b-cell-design.com](mailto:armelle.cuvillier@b-cell-design.com)

+33 (0) 555 123 021; +33 (0) 630 687 537

# Board of directors *Pharma expertises*



**Dr. Armelle CUVILLIER, PHD**  
President and Chief Scientific Officer  
Co-founder of B Cell Design  
Bordeaux II University  
Harvard Medical School  
Salvator de Bahia University  
HEC Business School (Challenge +)

**Christophe Jean**  
Former COO IPSEN, former Europe  
President Phama Division NOVARTIS

**Bertrand LOUVET**  
president of the "Ecole Nationale Supérieure de  
Chimie" in Rennes  
former director of Rhône Poulenc USA  
VP of the Business court of Nanterre.

**Jean-François MACQUIN**  
IBM, Rhone-Poulenc

**Administrator**  
**President**  
**CSO**  
**B Cell Design / ArkAb**



**Administrator**

**Observer**



**Chairman**  
**Board of Directors**



**Patrick LANGLOIS**  
Chairman of the board of directors,  
former CFO of Aventis-Sanofi  
Innate Pharma, Onxeo, Shire Pharmaceutical.

**Administrator**  
**CEO**  
**B Cell Design / ArkAb**



**Dr. Gaël CHAMPIER, PHD**  
CEO  
Co-founder of B Cell Design  
Limoges University

**Administrator**



**Dr. Annick SCHWEBIG, MD**  
Former VP of Bristol-Myers Squibb Europe  
Founder of the French subsidiary of Actelion  
Leem, Collectis, Inventiva companies

**Administrator**



**PIERRE LÉVI**  
founder Metman Investissements  
former CEO of the "Salins du Midi", Faurecia

**Scientific Board**




**Dr. Jean Yves Blay, MD, PhD, PU-PH,**  
Dir. Leon Bérard Institute, Innate Pharma  
Scientific Board

# TECHNOLOGICAL PLATFORM *Human chimeric ANTIBODIES: mab GAME*



**IgA** <1% IgA<sup>+</sup> B cell in spleen



**Lift the technological lock to generate and study IgA**

**hulgA<sup>HAMIGA</sup>** 60% IgA<sup>+</sup> B cell in spleen



# The context of the disease

---

## Colorectal cancer CRC

3rd most diagnosed cancer worldwide

**775 000** deaths/year Worldwide

**150** patients/day, in France  
learn that they have a colorectal cancer

**15 000** deaths/year, in France



# In terms of treatment

First-line chemotherapy

70% non-responders

KRAS gene mutation

50% treated

50%  
responders

IgA alternative  
Undervalued potential  
New features



## On late metastatic model of colorectal cancer

---

**Anti-CEA IgA demonstrates a significant higher therapeutic benefit on tumor size reduction than the Immunotherapy Gold Standard, the IgG anti-EGF receptor, ERBITUX<sup>®</sup>**

## On Chemo/Immunotherapy combined treatment protocol

---

**The orally administered Anti-CEA IgA reduces the tumoral burden while the anti-EGF receptor IgG, ERBITUX<sup>®</sup> failed to control tumor growth**





# Thank you for your attention

Armelle Cuvillier  
President/C.S.O

[armelle.cuvillier@b-cell-design.com](mailto:armelle.cuvillier@b-cell-design.com)

+33 (0) 555 123 021; +33 (0) 630 687 537